Merck & Co (NYSE: MRK) was the biggest spender in pharma M&A during July. The US pharma giant boldly splashed out around $10 ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...

Some high-profile healthcare names are at even cheaper valuations. For example, Merck is trading at a forward P/E of 8.7, ...

Merck has announced the acquisition of SpringWorks, which is expected to close this year, for an enterprise value of EUR 3 billion. While the deal appears expensive at an 18 times price/sales multiple ...

Meanwhile, mRNA vaccine maker Moderna is cutting around 500 jobs (10% of its workforce) as part of a commitment to save $1.5 ...

Woes for U.S. healthcare stocks have worsened this year driven partly by Trump administration policies, although some ...

Germany's Merck KGaA raised its full-year guidance for growth in underlying earnings, thanks to better prospects for its life-sciences and healthcare segments, but turned more cautious on sales.

Germany's Merck KGaA on Thursday raised its full-year operating earnings guidance, excluding the effect of harsh foreign ...

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

The highest-paying dividend stocks in the Dow Jones Industrial Average right now are Verizon Communications (NYSE: VZ), ...

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...